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Summary. Background: Statins [3-hydroxymethyl-3-methyl-
glutaryl coenzyme A (HMG-CoA) reductase inhibitors] and
antiplatelet therapy reduce the risk of atherosclerotic disease.
Besides a reduction of lipid levels, statins might also have
antithrombotic and anti-inflammatory properties, and anti-
platelet therapy reduces clot formation. We have studied the
risk of venous thrombosis with use of statins, other lipid-
lowering medication, and antiplatelet therapy. Materials and
methods:Patients with a first episode of deep vein thrombosis in
the leg or pulmonary embolism between March 1999 and
September2004were included in a largepopulation-based case–
control study (MEGAstudy). Control subjects were partners of
patients (53%) or recruited via a random-digit-dialing method
(47%). Participants reported different all-medication use in a
questionnaire. Results: Of 4538 patients, 154 used statins
(3.3%), as did 354 of 5914 control subjects (5.7%). The use of
statins [odds ratio (OR) 0.45; 95% confidence interval (CI)
0.36–0.56] but not other lipid-lowering medications (OR 1.22;
95% CI 0.62–2.43), was associated with a reduced venous
thrombosis risk as compared with individuals who did not use
any lipid-lowering medication, after adjustment for age, sex,
body mass index, atherosclerotic disease, antiplatelet therapy
and use of vitamin K antagonists. Different types and various
durations of statin therapy were all associated with a decreased
venous thrombosis risk. Antiplatelet therapy also reduced
venous thrombosis risk (OR 0.56; 95% CI 0.42–0.74). How-
ever, sensitivity analyses suggested that this effect is most likely
explained by a so-called healthy user effect. Simultaneous use
of medication most strongly reduced venous thrombosis risk.
Conclusion:These results suggest that the use of various types of
statins is associated with a reduced risk of venous thrombosis,
whereas antiplatelet therapy and other lipid-lowering medica-
tions are not.
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Introduction
Several clinical trials have demonstrated that 3-hydroxymethyl-
3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibi-
tors or statins prevent and reduce mortality and morbidity
among patients with cardiovascular disease [1–3]. It has been
suggested that the therapeutic benefits of statins are due not
only to their plasma low-density lipoprotein cholesterol-
lowering effect, but also to antithrombotic and anti-inflamma-
tory properties [4–11].
These so-called pleiotropic effects of statins may reduce the
risk for venous thrombosis, through inactivation of factor V,
FXIII and prothrombin. Both cohort and case–control studies
have shown risk reductions for venous thrombosis of between
22% and 58% with statin therapy[12–15]. However, previous
studies were small with respect to number of venous throm-
botic events that occurred, and the effects of various types and
duration of statin therapy have only been studied to a limited
extent [4,9,11–15].
The use of antiplatelet therapy has been extensively studied
in the context of arterial thrombosis, and is a cornerstone in the
prevention of atherosclerotic disease [16]. As platelets play a
role in the development of venous thrombi, it has been
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hypothesized that antiplatelet therapy may have a preventive
effect on venous thrombosis as well. In various studies, risk
reductions for venous thrombosis of between 5% and 50%
have been reported [17].
TheMultiple Environmental andGenetic Assessment of risk
factors for venous thrombosis (MEGA study) is a large
population-based case–control study including over 4000
patients with venous thrombosis. We studied the effects of
various types of statins, other lipid-lowering and antiplatelet
therapy and vitamin K antagonists in detail. Furthermore, we
studied combinations of these therapies as well as duration of
therapy, and we performed various subgroup and sensitivity
analyses.
Materials and methods
Subjects and data collection
Patients aged 18–70 years, with a first episode of deep vein
thrombosis (DVT) of the leg or pulmonary embolism (PE)
between March 1999 and September 2004, were recruited for
inclusion in the MEGA study from six anticoagulation clinics
in the Netherlands. Exclusion criteria were severe psychiatric
disease and lack of knowledge of Dutch. Among 6331 eligible
patients, 276 died before participating, 82 were in the end stage
of disease, and 917 refused to participate. Some patients
(n = 425) only provided a standardized mini-questionnaire by
telephone that did not contain information on medication use.
These patients were excluded from the present analyses.
Information regarding the diagnostic procedure was obtained
via hospital records and family physicians. Patients in whom
the diagnosis was considered probable or definite were
included, as has been described previously [18]. Patients who
were treated for a venous thrombosis but nevertheless had a
negative diagnostic procedure (n = 93) were excluded, result-
ing in a total of 4538 patients.
Control subjects were partners of patients (n = 3126, 53%)
or obtained via a random-digit-dialing (RDD) method
(n = 2788, 47%); they were all aged 18–70 years. The RDD
control subjects were recruited from the same geographical area
as the patients, and were frequency matched to the patients on
age and sex.The same exclusion criteriawere applied for control
subjects as for patients, resulting in 5914 participating control
subjects [18]. Participants gave written informed consent. This
study was approved by the Ethics Committee of the Leiden
University Medical Centre, Leiden, the Netherlands.
Participants were asked to fill in a standardized question-
naire within a few weeks after inclusion in the study. The index
date was defined as the date of venous thrombosis event for the
patients, and the date of completing the questionnaire for the
control subjects. The questionnaire provided information on
atherosclerotic and other diseases, weight, height, the use of
medication, and risk factors for venous thrombosis, such as
surgery and malignancies in the period prior to the index date.
Body mass index (BMI) was calculated by dividing weight (kg)
by height squared (m2). Atherosclerotic disease was defined as
current angina pectoris or a history of a transient ischemic
attack, stroke or myocardial infarction.
The use of medications in the 12 months before the index
date was self-reported in the questionnaire. Month and year of
start and end of therapy were asked for each type of
medication. Both brand names and active components were
reported. Current users were those individuals who used their
medication at the time of the venous thrombosis (patients) or
at the time of filling in the questionnaire (control subjects).
Duration of medication use was calculated in months.
Participants who did not provide the start date of use were
excluded from the analysis for duration of treatment.
Discharge letters of patients who did not provide a date of
use were used to confirm medication use at the time of the
thrombosis. Patients who started to use medication after the
index date were considered to be non-users. If no end date was
reported, participants were considered to have used the
medication at the time of the index date. Lipid-lowering
medication exposure was divided into two groups: statin
therapy (HMG-CoA reductase inhibitors, simvastatin, pra-
vastatin, atorvastatin, rosuvastatin, or fluvastatin), and other
lipid-lowering therapy (colestipol, colestyramin, acipimox,
bezafibrate, ciprofibrate, or gemfibrozil). Use of oral antiplat-
elet therapy (acetylsalicylic acid or aspirin, calcium carbasa-
late, clopidogrel, or dipyridamole) and use of vitamin K
antagonists (coumarins) before the index date were also
extracted from the questionnaire and discharge letters. When
patients did not report the date of vitamin K antagonist use, it
was assumed that vitamin K use started after the thrombosis.
These patients were considered to be non-users.
Statistical analyses
To determine whether exposure to the different types of
medications was associated with a risk reduction for venous
thrombosis as compared with individuals who did not use any
of these therapies, odds ratios (ORs) with 95% confidence
intervals (95% CIs) were calculated as estimates of relative risk.
Adjustment for potential confounding effects, such as age, sex,
BMI and atherosclerotic disease, and use of other therapies,
was performed by unconditional logistic regression.
Two sensitivity analyses were performed. The aim of the first
sensitivity analysis was to rule out a healthy user effect, as
individuals seeking preventive medication may differ in health
status from those who do not. In this analysis, we only included
statin or antiplatelet medication users with a clear indication
for therapy, that is, atherosclerotic disease (relatively sick
participants), and compared these users to those who did not
use statin or antiplatelet medication (non-users) without
atherosclerotic disease (relatively healthy participants).
A second sensitivity analysis was performed in very healthy
individuals without any comorbidities, that is, no malignancy,
diabetes, thyroid, kidney or lung diseases, rheumatoid arthritis
and multiple sclerosis or atherosclerotic disease, as a previous
report could not find a beneficial effect of statin therapy among
patients with these diseases [19]. SPSS version 12.0.1 for
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Windows (SPSS Inc., Chicago, IL, USA) was used for all
statistical analyses.
Results
Characteristics of the 4538 patients and 5914 control subjects
are shown in Table 1. No differences were found for age and
sex between patients and control subjects. Patients had a
slightly higher BMI, andmore often had atherosclerotic disease
as compared with control subjects.
Within the control group, statin and antiplatelet users were
more often male (55.6%) than non-users (45.4%), and most
statin and antiplatelet drug users were over 50 years of age
(87.5%). In this age group, current statin and antiplatelet drug
users were more often obese (BMI > 30 kg m)2, 22.9% vs.
15.0%), and more often had atherosclerotic disease (35.2% vs.
1.8%) and diabetes (17.3% vs. 4.3%), but malignancy (9.6%
vs. 7.8%) and surgery (10.8% vs. 8.2%) were as frequent in
users as in non-users. Statin users more often had diabetes, and
were more often obese as compared with antiplatelet drug
users; however, the latter group more often had atherosclerotic
disease.
Lipid-lowering medication
Of the patients, 154 currently used statins (3.3%), as did 354
of the control subjects (5.7%) (Table 2). Median duration of
statin therapy among patients was 25.0 months (range 2–
313), and that among control subjects was 29.5 months
(range 2–265). Current use of statins was associated with a
45% reduced risk of venous thrombosis (OR 0.55; 95% CI
0.46–0.67) as compared to non-use (Table 2). Adjustment for
age, sex, BMI, atherosclerotic disease and the use of
antiplatelet therapy or vitamin K antagonists led to a more
pronounced protective effect of statins (ORadj 0.45; 95% CI
0.36–0.56). Further adjustment for malignancy, diabetes and
surgery did not result in a different estimate (ORadj 0.46;
95% CI 0.37–0.58). Current use of other lipid-lowering
medications was not associated with a reduced risk of venous
thrombosis (OR 0.88; 95% CI 0.46–1.71); OR fully adjusted
for age, sex, BMI, atherosclerotic disease, statin, antiplatelet
therapy or vitamin K antagonists was 1.22 (95% CI 0.62–
2.43).
All types of statins were associated with a similarly reduced
risk of venous thrombosis (Table 3). Use of pravastatin showed
amore beneficial effect than simvastatin use (ORadj pravastatin
as compared with simvastatin 0.59; 95% CI 0.31–1.11).
Overall duration of statin therapy did not affect thrombosis
risk, with ORs of 0.50 (95% CI 0.27–0.91) for those who
started statins in the 2–6 months before the index date and 0.49
(95% CI 0.37–0.66) for those who had used statins for at least
2 years (test for trendP = 0.36). The risk reduction associated
with statin therapy among men (ORadj 0.38; 95% CI 0.29–
0.51) was slightly more pronounced than the risk reduction in
women (ORadj 0.47; 95% CI 0.34–0.65). Similarly, the risk
among those over 60 years of age (ORadj 0.32; 95% CI 0.23–
0.45) was more pronounced than the risk reduction in those
below 60 years of age (ORadj 0.53; 95% CI 0.40–0.71).
Among those without atherosclerotic disease (ORadj 0.41;
95% CI 0.32–0.53) or any comorbidities (ORadj 0.43;
95% CI 0.29–0.65), risk reductions were similar. The risk
reduction for PE with statin therapy was slightly less
(ORadj 0.56; 95% CI 0.43–0.75) than the risk reduction for
DVT (ORadj 0.31; 95% CI 0.23–0.42). When we contrasted
patients with each of the two control groups separately, current
statin therapy was associated with reduced risks for both
comparisons: RDD controls, ORadj 0.35 (95% CI 0.27–0.44);
and partner controls, ORadj 0.47 (95% CI 0.37–0.60). Among
those with artherosclerotic disease, the risk reduction with
statins was 0.47 (95% CI 0.31–0.71).
Antiplatelet therapy
Among the patients, 119 currently used antiplatelet therapy
(2.3%), as did 203 of the control subjects (3.4%) (Table 2).
Nearly all of them were treated with aspirin (97%). Current
antiplatelet therapy use was associated with a 23% reduced
risk of venous thrombosis (OR 0.76; 95% CI 0.60–0.95) as
compared to non-use. Adjustment for age, sex, BMI,
atherosclerotic disease, statin therapy, other lipid-lowering
medication or vitamin K antagonists led to a slightly stronger
protective effect of antiplatelet therapy (ORfully adj 0.56;
95% CI 0.42–0.74). Further adjustment for malignancy,
diabetes and surgery did not result in a different estimate.
ORs were lower in men (ORadj 0.49; 95% CI 0.34–0.70)
than in women (ORadj 0.60; 95% CI 0.38–0.95), and for PE
(ORadj 0.51; 95% CI 0.35–0.74) than for DVT (ORadj 0.61;
95% CI 0.43–0.87). Among those with atherosclerotic
disease, the risk reduction with aspirin was 0.40 (95% CI
0.26–0.60).
Table 1 Characteristics of patients and control subjects, all at the time of
the thrombosis or the index date
Patients
(n = 4538)
Controls
(n = 5914)
Age [years; median
(5th–95th percentile)]
49.6 (25.7–67.8) 48.3 (25.7–66.8)
Sex [women; n (%)] 2461 (54.2) 3181 (53.8)
BMI [kg m)2; median
(5th–95th percentile)]
26.2 (19.9–36.6) 25.0 (19.6–33.5)
Atherosclerotic disease,
n (%)
230 (5.1) 200 (3.4)
Self-reported medication
use, n (%)
2925 (64.5) 2941 (49.7)
Malignancies, n (%) 572 (12.6) 275 (4.6)
Diabetes, n (%) 183 (4.0) 198 (3.3)
Surgery, n (%) 1069 (23.6) 472 (8.0)
DVT, n (%) 2670 (58.9) –
PE, n (%) 1583 (35.0) –
DVT + PE, n (%) 285 (6.1) –
BMI, body mass index; DVT, deep vein thrombosis; PE, pulmonary
embolism.
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Vitamin K antagonists
Vitamin K antagonists were seldom used prior to the index
date. Their use was associated with a more than 50% reduced
risk of venous thrombosis (OR adjusted for age, sex, BMI,
atherosclerotic disease, statin therapy, other lipid-lowering
medication or antiplatelet therapy 0.46; 95% CI 0.23–0.92).
Further adjustments did not result in a different risk estimate.
Combinations of therapy
Statin therapy, other lipid-lowering medication, antiplatelet
therapy and vitamin K antagonists were often prescribed
simultaneously. When adjusted for age, sex and BMI, use of
statin therapy only (OR 0.58; 95% CI 0.46–0.73) and vita-
min K antagonists only (OR 0.56; 95% CI 0.24–1.30) were
both associated with a reduced risk of venous thrombosis as
compared to those who did not use statin, vitamin K
antagonists, other lipid-lowering medication or antiplatelet
therapy. Other lipid-lowering medication (ORadj 1.41;
95% CI 0.51–3.90) and antiplatelet therapy (ORadj 0.96;
95% CI 0.71–1.29) were not associated with a decreased
thrombosis risk (Table 4). After adjustment for atherosclerotic
disease, risks were further reduced. Other lipid-lowering
medication use remained associated with a higher risk of
venous thrombosis. Simultaneous use of therapy was associ-
ated with the largest reduction in risk for both combinations of
statin with antiplatelet therapy (ORadj 0.38; 95% CI 0.25–
0.57), and statin therapy with vitamin K antagonists
(ORadj 0.21; 95% CI 0.06–0.74).
Sensitivity analyses
Two sensitivity analyses were performed to rule out a possible
healthy user effect. First, relatively sick participants with
atherosclerotic disease who used statins had a lower risk of
venous thrombosis than relatively healthy participants who
were non-users without atherosclerotic disease (ORadj 0.53;
95% CI 0.43–0.65). However, antiplatelet therapy did not
reduce venous thrombosis risk in this high-risk population with
a clear indication for therapy (OR 0.90; 95% CI 0.65–1.24).
Second, in very healthy participants without diseases, statin
therapy use was still associated with a reduced risk (ORadj 0.44;
95% CI 0.29–0.67), which again was not the case for
antiplatelet therapy (ORadj 0.95; 95% CI 0.50–1.77).
Discussion
Individuals who used statin therapy or vitamin K antagonists
were found to have an almost 60% reduced risk of venous
thrombosis. This risk reduction was similar in users of all
different types of statins. Other lipid-lowering therapy did not
reduce the risk of venous thrombosis. Antiplatelet therapy
seemed to reduce the risk of venous thrombosis, but this effect
was largely explained by a so-called healthy user effect, which
will be discussed below.
Lipid-lowering medication
Our results confirm the results of previous studies suggesting
similar reductions in venous thrombosis risk with statin
therapy [12–15]. In the HERS study, the use of statins was
associated with a 50% reduced risk of venous thrombosis [12],
and in a Canadian cohort study, the risk reduction was 22% as
compared to non-users [13]. One drawback of these studies was
Table 2 Association of statin, other lipid-lowering or antiplatelet therapy or vitamin K antagonists and the risk of venous thrombosis
Lipid-lowering medication
Patients
(n = 4538)
Controls
(n = 5914) OR (95% CI) OR (95% CI)* OR (95% CI) OR (95% CI)
Statins
Non-users 4384 5560 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Users 154 354 0.55 (0.46–0.67) 0.50 (0.42–0.62) 0.41 (0.33–0.51) 0.45 (0.36–0.56)
Other lipid-lowering medication
Non-users 4523 5892 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Users 15 22 0.88 (0.46–1.71) 0.90 (0.46–1.74) 0.84 (0.43–1.64) 1.22 (0.62–2.43)
Oral antiplatelet therapy
Non-users 4419 5711 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Users 119 203 0.76 (0.60–0.95) 0.70 (0.56–0.89) 0.49 (0.37–0.65) 0.56 (0.42–0.74)
Vitamin K antagonists
Non-users 4527 5880 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Users 11 34 0.42 (0.21–0.83) 0.41 (0.21–0.81) 0.37 (0.19–0.74) 0.46 (0.23–0.92)
CI, confidence interval; OR, odds ratio. *ORs adjusted for age, sex and body mass index (BMI) (kg m)2). ORs adjusted for age, sex, BMI (kg m)2)
and atherosclerotic disease. ORs adjusted for age, sex, BMI (kg m)2), atherosclerotic disease, and the other medications.
Table 3 Association of different types of statin therapy and the risk of
venous thrombosis
Patients Controls OR (95% CI)* OR (95% CI)
Non-users 4384 5560 1 (reference)
Type of statin
Simvastatin 69 144 0.51 (0.38–0.69) 1 (reference)
Atorvastatin 61 136 0.48 (0.35–0.65) 0.88 (0.57–1.35)
Pravastatin 18 53 0.34 (0.20–0.65) 0.59 (0.31–1.11)
Rosuvastatin 3 11 0.33 (0.09–1.21) 0.45 (0.12–1.77)
Fluvastatin 7 10 0.81 (0.31–2.14) 1.51 (0.54–4.27)
CI, confidence interval; OR, odds ratio. *ORs adjusted for age, sex,
body mass index (kg m)2) and atherosclerotic disease. Four patients
used more than one type of statin.
Statins and aspirin and venous thrombosis risk 517
 2008 International Society on Thrombosis and Haemostasis
that they included a selective population; in HERS, only
postmenopausal women with coronary disease were included,
whereas the Canadian cohort study included a rather healthy
(no malignancy or cardiovascular disease) population of over
65 years of age. One study even suggested that statin therapy
only would decrease the risk of provoked thrombosis, but not
of idiopathic thrombosis [19]. Similar risk reductions (58%) for
venous thrombosis with statin therapy were observed in two
other case–control studies [14,15].
As our study was large, we could study the effects of statins
in more detail. One previous study [15] showed that only
simvastatin reduced the risk of venous thrombosis, and there
was even a suggestion of an increased risk of venous
thrombosis for those using pravastatin. We showed that all
different types of statins seemed to reduce the risk of venous
thrombosis. Pravastatin appeared to be slightly more beneficial
than simvastatin. We did not find an association between the
duration of statin therapy and the risk of venous thrombosis.
Short-term and long-term statin therapy equally reduced the
risk of venous thrombosis, suggesting an immediate effect of
statins. Unfortunately, we did not have any information
regarding the dose of medication. One study showed that high-
dose statin therapy seemed to be more beneficial than low-dose
statin therapy [15].
We have not found any suggestion of a possible protective
effect of the use of other lipid-lowering medications, thereby
confirming the results of other studies [14,15] and even a
randomized controlled trial on the effects of fenofibrate [20].
Nevertheless, an earlier study showed that high triglyceride
levels are associated with an increased risk of venous throm-
bosis [21], suggesting that lipid-lowering might decrease venous
thrombosis risk. Furthermore, another study has shown that
fibrates decrease the levels of fibrinogen, whereas statins do not
[22]. Therefore, we do not have an explanation for this
increased risk, besides a possible sharing of risk factors between
those receiving other lipid-loweringmedications and those with
a high risk of venous thrombosis. The number of individuals
treated with fibrates in our study was low, as statin therapy is
the first recommended therapy in the Netherlands.
Antiplatelet therapy
Previous studies have shown that the use of antiplatelet therapy
is associated with a 22% risk reduction for recurrent athero-
sclerotic disease [16]. Conversely, aspirin has been shown to be
less effective in preventing first atherosclerotic disease (risk
reductions of 12–14%) [17]. A review showed that in patients
with a high risk of venous thrombosis, such as surgery patients,
the use of antiplatelet therapy is associated with a reduction of
the risk of venous thrombosis of approximately 30% [23].
Regarding first unprovoked venous thrombotic events, a
relatively small case–control study revealed risk reductions of
up to 50% associated with antiplatelet therapy [24]. However,
in a long-lasting randomized controlled trial among apparently
healthy women, the risk of venous thrombosis was only slightly
attenuated by low-dose aspirin [25]. Our population-based
study confirms these results. We also showed that antiplatelet
therapy seemed to be effective among a high-risk group (only
those with arterial thrombosis) but not in those with a low risk.
Furthermore, sensitivity analyses seem to suggest that the effect
may be introduced by confounding by a so-called healthy user
effect; that is, those who choose to use aspirin for primary
prevention are healthy, health-conscious individuals.
When different studies are compared, case–control studies
seem to show a larger beneficial effect of statins than was
found in cohort studies. Cohort studies have the drawback
that they usually assess indicators at baseline, long before the
occurrence of the disease, resulting in a possible dilution of the
effect when individuals have stopped or started therapy during
follow-up. Case–control studies have the benefit of gathering
information about medication use just prior to the thrombo-
sis. As there is a time lag in cohort studies between assessment
of medication use and the event, case–control studies might be
better for showing the association between medication use and
the risk of venous thrombosis. Case–control studies have the
drawback of recall bias. In our study, medication use was
assessed via self-report, and we did not have the possibility of
confirming medication use via pharmacy records. Therefore,
patients might have recalled their medication differently from
Table 4 Combination of statin, antiplatelet and vitamin K antagonists and the risk of venous thrombosis
Medication Patients Controls OR (95% CI)* OR (95% CI)
Non-users 4281 5434 1 (reference) 1 (reference)
Only one therapy
Statin therapy only 115 226 0.58 (0.46–0.73) 0.49 (0.39–0.62)
Other lipid-lowering therapy only 8 7 1.41 (0.51–3.90) 1.44 (0.52–4.00)
Oral antiplatelet therapy only 85 101 0.96 (0.71–1.29) 0.62 (0.45–0.87)
Oral vitamin K antagonists only 8 18 0.56 (0.24–1.30) 0.49 (0.21–1.15)
Simultaneous use
Statin therapy and other lipid-lowering therapy 4 10 0.52 (0.16–1.17) 0.46 (0.14–1.53)
Statin therapy and oral antiplatelet therapy 31 96 0.38 (0.25–0.57) 0.21 (0.13–0.32)
Statin therapy and vitamin K antagonists 3 16 0.21 (0.06–0.74) 0.14 (0.04–0.47)
Other lipid-lowering therapy and antiplatelet therapy 2 0 Could not be estimated
Statin therapy, other lipid-lowering therapy and oral
antiplatelet therapy
1 5 0.23 (0.03–1.96) 0.12 (0.01–1.08)
CI, confidence interval; OR, odds ratio. None of the participants used a combination of oral vitamin K antagonists and antiplatelet therapy. *ORs
adjusted for age, sex and body mass index (BMI) (kg m)2). ORs adjusted for age, sex, BMI (kg m)2) and atherosclerotic disease.
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control subjects. However, in the Netherlands, statins and
low-dose aspirin require a doctors prescription, and we expect
that both patients and control subjects reported use of these
specific medications. Therefore, we do not believe that
misclassification, if present, would have had a large impact.
Furthermore, if patients had reported their treatment more
accurately than the control subjects, this would have resulted
in an underestimation of the real effect of statins and
antiplatelet therapy.
Atherosclerotic disease has been described as a potential risk
factor for venous thrombosis [26–28]. A debate as to whether
they share the same risk factors or whether having atheroscle-
rotic disease is a risk factor itself is still ongoing [29]. If
atherosclerotic disease is indeed a risk factor, this might distort
the association between statins, antiplatelet therapy and venous
thrombosis, which is the reason why we adjusted for athero-
sclerotic disease. The simultaneous use of comedications may
also influence the risk. After adjustments, the beneficial effect
of statins, therapy with antiplatelet drugs or vitamin K
antagonists was not affected by the use of other medications.
Simultaneous use of oral vitamin K antagonists and statins
showed the largest reduction in risk.
It has been suggested that the beneficial effect of statins and
antiplatelet therapy other than on atherosclerotic disease may
be explained by the so-called healthy user effect [30–33]. This
effect would occur when those with a risk profile leading to a
reduced risk of thrombosis would preferentially seek treatment
with statins or antiplatelet therapy. Furthermore, patients
regularly using statins or antiplatelet therapy for preventive
reasons may have a healthier lifestyle and may be more
compliant users of medications, factors that are known to lead
to overoptimistic estimates of effects [33]. We found no
indication of a healthy user effect for statin therapy, as users
were less healthy than non-users, being more often obese and
more often having diabetes. Furthermore, we performed a
sensitivity analysis comparing the risk in unhealthy users of
statin therapy (only those with atherosclerotic disease) with
that in healthy non-users. As the risk of venous thrombosis was
still decreased, this contradicts a possible healthy user effect for
statin therapy. We did find indications that the healthy user
effect may explain the effect of antiplatelet therapy, as the
sensitivity analyses largely removed the effect of antiplatelet
therapy on the risk of venous thrombosis.
In conclusion, our data suggest a protective effect of statin
therapy regarding the risk of venous thrombosis, independent
of age, sex, BMI and atherosclerotic disease and the use of
comedication. Although antiplatelet therapy also seemed to
reduce venous thrombosis risk, this effect might be largely
explained by a healthy user effect.
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